Literature DB >> 18670269

Probe ablative treatment for small renal masses: cryoablation vs. radio frequency ablation.

Raj K Goel1, Jihad H Kaouk.   

Abstract

PURPOSE OF REVIEW: Localized renal cell carcinoma has an excellent 5-year survival when treated surgically. Apart from extirpative treatment, ablative techniques are becoming more popular to minimize patient morbidity. Clinically, radio frequency ablation and cryoablation can be performed percutaneously or laparoscopically. Oncological effectiveness of ablative techniques is encouraging as 3-year data are emerging. Our review highlights the current literature demonstrating the effectiveness of cryoablation and radio frequency ablation performed laparoscopically or percutaneously. RECENT
FINDINGS: Cryoablation performed laparoscopically or percutaneously offers excellent oncological outcomes with single-session therapy. With 3-year cancer-specific survival of 98%, laparoscopic cryoablation is safe and can be performed with minimal insult to overall renal function. Local recurrence rates and metastatic progression also seem to favor cryoablation over radio frequency ablation (4.6 vs. 11.7% and 1.2 vs. 2.3%, respectively). Radio frequency ablation also offers similar survival rates; however, re-treatment rates are higher (8.8%). Radio frequency ablation also carries a higher rate of collecting system injuries when performed percutaneously.
SUMMARY: Cryoablation and radio frequency ablation are effective treatment modalities for small renal masses in the infirm patient. Given patient and technical variability, superiority of either radio frequency ablation or cryoablation cannot be confirmed based on available literature. However, there is a trend towards higher recurrence and re-treatment rates after radio frequency ablation.

Entities:  

Mesh:

Year:  2008        PMID: 18670269     DOI: 10.1097/MOU.0b013e32830a735b

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  14 in total

Review 1.  Image-guided percutaneous ablation of renal tumors: outcomes, technique, and application in urologic practice.

Authors:  Adam C Mues; Jaime Landman
Journal:  Curr Urol Rep       Date:  2010-02       Impact factor: 3.092

Review 2.  Results of kidney tumor cryoablation: renal function preservation and oncologic efficacy.

Authors:  Adam C Mues; Jaime Landman
Journal:  World J Urol       Date:  2010-04-23       Impact factor: 4.226

Review 3.  Percutaneous ablation of adrenal tumors.

Authors:  Aradhana M Venkatesan; Julia Locklin; Damian E Dupuy; Bradford J Wood
Journal:  Tech Vasc Interv Radiol       Date:  2010-06

Review 4.  Percutaneous ablation in the kidney.

Authors:  Aradhana M Venkatesan; Bradford J Wood; Debra A Gervais
Journal:  Radiology       Date:  2011-11       Impact factor: 11.105

Review 5.  Interventional radiology of the adrenal glands: current status.

Authors:  Anna Maria Ierardi; Mario Petrillo; Francesca Patella; Pierpaolo Biondetti; Enrico Maria Fumarola; Salvatore Alessio Angileri; Filippo Pesapane; Antonio Pinto; Gianlorenzo Dionigi; Gianpaolo Carrafiello
Journal:  Gland Surg       Date:  2018-04

Review 6.  Mechanisms of cryoablation: clinical consequences on malignant tumors.

Authors:  J G Baust; A A Gage; T E Bjerklund Johansen; J M Baust
Journal:  Cryobiology       Date:  2013-11-13       Impact factor: 2.487

7.  Real-time probe tracking using EM-optical sensor for MRI-guided cryoablation.

Authors:  Wenpeng Gao; Baichuan Jiang; Daniel F Kacher; Barry Fetics; Erez Nevo; Thomas C Lee; Jagadeesan Jayender
Journal:  Int J Med Robot       Date:  2017-11-28       Impact factor: 2.547

Review 8.  Imaging and management of the incidentally discovered renal mass.

Authors:  Jonathon Willatt; Isaac R Francis
Journal:  Cancer Imaging       Date:  2009-10-02       Impact factor: 3.909

9.  Current status of ablative therapies for renal tumors.

Authors:  Adam C Mues; Jaime Landman
Journal:  Indian J Urol       Date:  2009 Oct-Dec

10.  Ablative therapies for small renal tumors.

Authors:  Jan Adamowicz; Jakub Tworkiewicz; Jerzy Siekiera; Tomasz Drewa
Journal:  Contemp Oncol (Pozn)       Date:  2013-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.